Literature DB >> 93585

Characteristics and genetic control of NK-cell-mediated cytotoxicity activated by naturally acquired infection in the mouse.

E A Clark, P H Russell, M Egghart, M A Horton.   

Abstract

Most and perhaps all natural-cell-mediated cytotoxicity (NCMC) may be activated by a response to exogenous infections. Specific-pathogen-free (SPF) mice have little or no natural killer (NK) cell activity, but when they are relocated in conventional conditions, they develop strong NCMC within 2 to 3 days. Unlike other SPF animals, hypothymic nude mice display good NCMC which is further augmented upon their entry into a pathogenic environment. The ontogeny, genetic control and other features of pathogen-activated NCMC resemble those previously described for NK cells. An H2-D region NCMC regulatory gene is active in either a homozygous or heterozygous state, but to be operative seems to require the presence of an additional complementing locus, which maps outside the H-2 complex. It is proposed that H-2 influences NCMC levels by affecting the expression or immunogenicity of NK cell-activating determinants. Recently activated NK cells were non-adherent and lacked Ia and Thy-1 determinants. NCMC was not affected by treatment with monoclonal high-titer Thy-1.2 antisera and complement. However, an Ly-6.2 antiserum did contain anti-NK cytotoxic activity, which was shown by absorption analysis to be distinct from anti-Ly-6.2 activity. The NK antigen has a strain distribution pattern distinct from Ly-5 and other Ly markers, but may be related or identical to NK-1.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 93585     DOI: 10.1002/ijc.2910240525

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  10 in total

Review 1.  Natural pathogens of laboratory mice, rats, and rabbits and their effects on research.

Authors:  D G Baker
Journal:  Clin Microbiol Rev       Date:  1998-04       Impact factor: 26.132

2.  Genetic determinants of lung virus titers and resistance to lethal Sendai virus pneumonia.

Authors:  D G Brownstein; S Winkler
Journal:  Arch Virol       Date:  1987       Impact factor: 2.574

Review 3.  Natural killer cells in resistance to virus-infected cells.

Authors:  B Rager-Zisman; B R Bloom
Journal:  Springer Semin Immunopathol       Date:  1982

4.  Activation of natural killer (NK) cells in vivo with H-2 and non-H-2 alloantigens.

Authors:  E A Clark; R D Holly
Journal:  Immunogenetics       Date:  1981       Impact factor: 2.846

5.  Natural killer cells are a source of interferon gamma that drives differentiation of CD4+ T cell subsets and induces early resistance to Leishmania major in mice.

Authors:  T M Scharton; P Scott
Journal:  J Exp Med       Date:  1993-08-01       Impact factor: 14.307

6.  Mutations in mice that influence natural killer (NK) cell activity.

Authors:  E A Clark; L D Shultz; S B Pollack
Journal:  Immunogenetics       Date:  1981-03-01       Impact factor: 2.846

7.  Target-effector interactions in the rat NK cell system. II. Effects of interferon on lytic efficiency and on pre-NK cells in various organs, rat strains and during ontogeny.

Authors:  J P Flexman; G R Shellam
Journal:  Clin Exp Immunol       Date:  1984-01       Impact factor: 4.330

8.  Role of natural killer cells in control of cancer metastasis.

Authors:  N Hanna
Journal:  Cancer Metastasis Rev       Date:  1982       Impact factor: 9.264

Review 9.  Immune Relevant and Immune Deficient Mice: Options and Opportunities in Translational Research.

Authors:  Enrico Radaelli; Sara F Santagostino; Rani S Sellers; Cory F Brayton
Journal:  ILAR J       Date:  2018-12-31

10.  Natural killer (NK) cell response to virus infections in mice with severe combined immunodeficiency. The stimulation of NK cells and the NK cell-dependent control of virus infections occur independently of T and B cell function.

Authors:  R M Welsh; J O Brubaker; M Vargas-Cortes; C L O'Donnell
Journal:  J Exp Med       Date:  1991-05-01       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.